GlassScriptPhysician profile
Alia Jamison-Dinowitz
NPI 1942862453
$2,718.80
in general payments reported to CMS, 2019-2025
33 companies · $559 in 2025
The $559 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $586 · 2022: $279 · 2023: $609 · 2024: $686 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,853.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $311.44 | 2022-2025 | Vyepti |
| Novo Nordisk INC | $311.12 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $310.37 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $291.37 | 2021-2025 | Benlysta, Trelegy Ellipta |
| Sanofi Pasteur INC. | $219.82 | 2021-2025 | |
| Abbvie INC. | $172.69 | 2021-2025 | |
| Csl Behring | $158.67 | 2021-2024 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $88.58 | 2021-2024 | Takhzyro |
| Merck Sharp & Dohme LLC | $69.77 | 2023-2025 | Gardasil 9, Vaxelis, Capvaxive |
| Pfizer INC. | $69.56 | 2023-2025 | |
| Dexcom, INC. | $62.90 | 2021-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $60.03 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $51.37 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $45.65 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $43.38 | 2022-2024 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $40.70 | 2022-2023 | Thinprep 2000 Processor, Aptima |
| Alk-Abello, INC | $38.64 | 2023 | Ragwitek, Odactra, Grastek |
| Xeris Pharmaceuticals, INC. | $38.32 | 2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.92 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $29.56 | 2024 | Voquezna |
| Gilead Sciences, INC. | $27.16 | 2025 | |
| Biocryst US Sales Co., LLC | $26.03 | 2025 | Orladeyo |
| Regeneron Healthcare Solutions, INC. | $25.49 | 2023 | Dupixent |
| Esperion Therapeutics, INC. | $24.71 | 2021 | |
| Electromed, INC. | $23.46 | 2024 | Smartvest |
| Biohaven Pharmaceuticals, INC. | $22.67 | 2021 | |
| Immedica Pharma US, INC. | $20.12 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.98 | 2022 | |
| Phadia US INC. | $18.15 | 2024 | Immunocap |
| Octapharma USA, INC. | $17.79 | 2023 | Panzyga |
| Philips North America LLC | $16.78 | 2025 | Vest Therapy Und |
| Seqirus USA INC | $14.67 | 2021 | |
| Organon LLC | $10.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alia Jamison-Dinowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.